<DOC>
	<DOCNO>NCT00128739</DOCNO>
	<brief_summary>Twenty-four ( 2 x 12 ) patient intestinal graft versus host disease ( GVHD ) Grades 2 , 3 4 treat budesonide 3mg three time daily placebo 12 week . All patient receive cyclosporine mouth ( po ) prednisone intravenous ( IV ) methylprednisone start dose 2mg/kg/day ( standard anti-GVHD treatment ) . Doses steroid decrease approximately 10 % 10mg per week ( depend upon patient ’ weight ) upon response therapy , define decrease volume diarrhea 50 % per day , decrease abdominal pain presence bloody stool . Patients Grades 3 4 withdrawn study response one week therapy . Patients Grade 2 may continue decrease prednisone dose response achieve .</brief_summary>
	<brief_title>Treatment Gastro-Intestinal and/or Hepatic Graft Versus Host Disease With Budesonide Patients Following Peripheral Blood Stem Cell Transplantation</brief_title>
	<detailed_description>Graft versus host disease ( GVHD ) one common complication bone marrow transplantation ( BMT ) . Targets GVHD gastro-intestinal tract ( GIT ) liver skin , cause severe diarrhea mucosal aberration hepatitis cause life threaten liver failure . As result mucosal aberration general immuno-suppression , cause GVHD process anti GVHD therapy , patient highly susceptible severe , life threaten infection usually originate GIT . Systemic steroids backbone anti GVHD therapy . However , GVHD systemic steroid administer prolonged duration high dos , thus cause prolong immune suppression , expose patient steroid side effect hypertension , diabetes , cataract formation etc . Budesonide steroid combine topical anti-inflammatory activity high first-pass hepatic extraction . It show effective treatment inflammatory bowel disease result slightly less systemic steroid few steroid-related adverse reaction . Except influence gut , budesonide also show benefit inflammatory hepatic condition primary biliary cirrhosis , liver transplantation autoimmune hepatitis . Recently , show budesonide effective treatment acute GIT GVHD . The investigator propose evaluate effect budesonide GIT hepatic GVHD follow study . Patients : Twelve patient allogenic peripheral blood stem cell transplantation ( PBSCT ) grade &gt; = 2 GIT and/or hepatic GVHD prospectively compare 12 placebo control . Inclusion Criteria : - Clinical biopsy proven grade &gt; /= 2 GIT AND/OR hepatic GVHD . Exclusion Criteria : - Preventive antimicrobial treatment ( exception Resprim ) somatostatin GIT GVHD patient . - Anti-GVHD treatment steroid ( maximal dose ≤ 2 mg/kg methylprednisolone ) cyclosporine A tacrolimus . Study Protocol : All patient assess GVHD score ( organ general ) accord standard criterion test inclusion follow parameter – - Colon and/or liver biopsy GVHD staging ( include number crypt abscess ) . - Liver function test - blood albumin , AST , ALT , GGTP , Alk Phos , LDH , bilirubin , coagulation function , cholesterol . - Stool - volume frequency . - Radiological – CT scan mucosal edema , wall thickening ascites . - Kidney function test – blood creatinine , creatinine clearance . - Blood pressure . - Fasting blood glucose . If normal – oral glucose tolerance test , glycosylated hemoglobin . - Ophthalmologist evaluation cataract formation IOP . - GIT absorption assessment - xylose absorption . - Microbiological - stool culture stool CDT , CMV PCR , culture CMV blood urine . - Bone density – ultrasound . After inclusion patient treat budesonide 9 15mg per day divide dos placebo . Other anti-GVHD treatment ursodeoxycholic acid withheld taper try . Study parameter : - LFT , albumin , PT , cholesterol , renal function , stool volume frequency , CMV culture PCR , clinical GVHD stag - every 2 week . - Xylose test – every month . - Ophthalmologist evaluation , diabetes control CT scan – every 3 month . - GIT and/or liver biopsy GVHD staging ( include number crypt abscess ) CMV PCR , bone density – every 6 month - Blood , urine stool culture every febrile episode . Study duration : 14 week . End point : - Hospitalizations : due GVHD and/or due infection . - Overall GIT hepatic GVHD staging . - Time response . - Maximal daily diarrhea ( volume frequency ) . - Weight . - Liver function test . - Cataract formation IOP . - TNF level . - Albumin . - TPN consumption . - Bone density . - Hypertension . - Diabetes – presence control . - Febrile episode . - Positive culture . - Days antibiotic therapy . - Survival .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Patients clinical biopsy proven Grades 2 , 3 4 intestinal GVHD Patients negative stool culture Male female patient age 18 – 70 year Signed write informed consent patient Uncertain GVHD diagnosis ( cause intestinal disease possible ) Severe disease may influence patient prognosis Contraindication use steroid Patient ’ inability swallow study medication Concurrent use nonsteroidal antiinflammatory drug ( NSAID ) Known spontaneous iatrogenic disturbance thrombocyte aggregation blood clotting . Kidney dysfunction creatinine level high 2mg/dl Patients preventative antimicrobial therapy exception Resprim® ( sulfamethoxazole trimethoprim ) Patients take somatostatin Patients take antiGVHD medication exception steroid ( maximum dose prednisone methylprednisolone 2mg/kg/day ) cyclosporine A tacrolimus Pregnancy lactation Insufficient contraception protection Participation another clinical study within last 30 day . Mental condition render patient unable understand nature scope possible consequence study and/or evidence uncooperative attitude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2005</verification_date>
</DOC>